Bristol R&D In Brief
Executive Summary
Bristol Glucophage exclusivity: Bristol is unable to give 2002 guidance due to uncertainty surrounding Glucophage exclusivity, CEO Peter Dolan told a Nov. 7 update on the company's R&D program. "As this could be a meaningful contributor to our sales and earnings and because we maintain that our pediatric label legally entitles us an additional three years of exclusivity, any statements or stated assumptions about 2002 for the Glucophage family...could jeopardize this rapidly evolving situation." Bristol "appears to be close to knowing whether there'll be legislation affecting our rights...and what the FDA will be doing"...
You may also be interested in...
Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril
Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril
Bristol Readies For Glucophage Generics: Adds 600 Reps, Refiles Vanlev
Bristol-Myers Squibb will expand its sales force in 2002 despite an expected $1.7 bil. drop in Glucophage revenues due to the launch of metformin generics